• Treffer 100 von 1399
Zurück zur Trefferliste

Translational pharmacometric evaluation of typical antibiotic broad-spectrum combination therapies against staphylococcus aureus exploiting in vitro information

  • Broad-spectrum antibiotic combination therapy is frequently applied due to increasing resistance development of infective pathogens. The objective of the present study was to evaluate two common empiric broad-spectrum combination therapies consisting of either linezolid (LZD) or vancomycin (VAN) combined with meropenem (MER) against Staphylococcus aureus (S. aureus) as the most frequent causative pathogen of severe infections. A semimechanistic pharmacokinetic-pharmacodynamic (PK-PD) model mimicking a simplified bacterial life-cycle of S. aureus was developed upon time-kill curve data to describe the effects of LZD, VAN, and MER alone and in dual combinations. The PK-PD model was successfully (i) evaluated with external data from two clinical S. aureus isolates and further drug combinations and (ii) challenged to predict common clinical PK-PD indices and breakpoints. Finally, clinical trial simulations were performed that revealed that the combination of VAN-MER might be favorable over LZD-MER due to an unfavorable antagonisticBroad-spectrum antibiotic combination therapy is frequently applied due to increasing resistance development of infective pathogens. The objective of the present study was to evaluate two common empiric broad-spectrum combination therapies consisting of either linezolid (LZD) or vancomycin (VAN) combined with meropenem (MER) against Staphylococcus aureus (S. aureus) as the most frequent causative pathogen of severe infections. A semimechanistic pharmacokinetic-pharmacodynamic (PK-PD) model mimicking a simplified bacterial life-cycle of S. aureus was developed upon time-kill curve data to describe the effects of LZD, VAN, and MER alone and in dual combinations. The PK-PD model was successfully (i) evaluated with external data from two clinical S. aureus isolates and further drug combinations and (ii) challenged to predict common clinical PK-PD indices and breakpoints. Finally, clinical trial simulations were performed that revealed that the combination of VAN-MER might be favorable over LZD-MER due to an unfavorable antagonistic interaction between LZD and MER.zeige mehrzeige weniger

Metadaten exportieren

Weitere Dienste

Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Verfasserangaben:Sebastian G. Wicha, Wilhelm HuisingaORCiDGND, Charlotte KloftORCiDGND
DOI:https://doi.org/10.1002/psp4.12197
ISSN:2163-8306
Pubmed ID:https://pubmed.ncbi.nlm.nih.gov/28378945
Titel des übergeordneten Werks (Englisch):CPT: pharmacometrics & systems pharmacology
Verlag:Wiley
Verlagsort:Hoboken
Publikationstyp:Wissenschaftlicher Artikel
Sprache:Englisch
Datum der Erstveröffentlichung:05.04.2017
Erscheinungsjahr:2017
Datum der Freischaltung:12.04.2022
Band:6
Seitenanzahl:11
Erste Seite:512
Letzte Seite:522
Organisationseinheiten:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Mathematik
DDC-Klassifikation:5 Naturwissenschaften und Mathematik / 51 Mathematik / 510 Mathematik
Peer Review:Referiert
Publikationsweg:Open Access / Gold Open-Access
DOAJ gelistet
Lizenz (Deutsch):License LogoCC-BY-NC-ND - Namensnennung, nicht kommerziell, keine Bearbeitungen 4.0 International
Verstanden ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.